Table 1.
Overview of evaluable treatments per patient
| Patient ID | Evaluable treatment 1 | Response 1 | Evaluable treatment 2 | Response 2 | Evaluable treatment 3 | Response 3 | Mutational status | PDO origin | Stage at presentation | Sidedness |
|---|---|---|---|---|---|---|---|---|---|---|
| 04 | 5-FU | SD | 5-FU & irinotecan | SD | 5-FU & oxaliplatin | PR | RAS mutant | Metastatic | IV | Left |
| 06 | 5-FU | SD | RAS mutant | Metastatic | IV | Left | ||||
| 07 | 5-FU | SD | RAS mutant | Metastatic | IV | Left | ||||
| 11 | 5-FU | PD | Wildtype | Metastatic | IV | Right | ||||
| 16 | 5-FU | SD | Panitumumab | PD | BRAF mutant | Primary | IV | Right | ||
| 18 | 5-FU | PD | Wildtype | Metastatic | III | Rectum | ||||
| 01 | Irinotecan | SD | RAS mutant | Metastatic | II | Rectum | ||||
| 02 | 5-FU & irinotecan | SD | RAS mutant | Metastatic | III | Right | ||||
| 23 | 5-FU & irinotecan | SD | Panitumumab | SD | BRAF mutant | Metastatic | III | Left | ||
| 20 | 5-FU & irinotecan | PD | ||||||||
| 20 | 5-FU & oxaliplatin | PD | RAS mutant | Primary | IV | Left | ||||
| 03 | 5-FU & oxaliplatin | PD | RAS mutant | Primary | IV | Right | ||||
| 05 | 5-FU & oxaliplatin | PR | RAS mutant | Primary | IV | Right | ||||
| 08 | 5-FU & oxaliplatin | PR | Panitumumab | SD | Wildtype | Metastatic | IV | Rectum | ||
| 09 | 5-FU & oxaliplatin | SD | BRAF mutant | Metastatic | IV | Left | ||||
| 10 | 5-FU & oxaliplatin | PR | Panitumumab | SD | Wildtype | Metastatic | IV | Left | ||
| 12 | 5-FU & oxaliplatin | PR | 5-FU & irinotecan | SD | Panitumumab | SD | Wildtype | Metastatic | IV | Left |
| 13 | 5-FU & oxaliplatin | SD | Irinotecan | SD | RAS mutant | Metastatic | IV | Left | ||
| 14 | 5-FU & oxaliplatin | PR | 5-FU & irinotecan | PR | Wildtype | Metastatic | III | Rectum | ||
| 15 | 5-FU & oxaliplatin | PR | 5-FU & irinotecan | SD | Panitumumab | SD | Wildtype | Metastatic | III | Rectum |
| 17 | 5-FU & oxaliplatin | PR | 5-FU & irinotecan | SD | RAS mutant | Metastatic | IV | Right | ||
| 19 | 5-FU & oxaliplatin | PD | Wildtype | Metastatic | III | Left | ||||
| 21 | 5-FU & oxaliplatin | PD | Wildtype | Metastatic | II | Right | ||||
| 22 | Panitumumab | PR | Wildtype | Metastatic | IV | Left |
Table describing the evaluable treatments, ranked per primary evaluable treatment. The first, second and third lines after organoid establishment are shown for each patient, along with the patient’s best RECIST response during treatment. The RAS/BRAF mutational status of the original tumour, PDO origin, tumour stage at presentation and primary tumour location (sidedness) are presented. All patients had a proficient mismatch repair (pMMR) tumour. Patient 20 was resistant to FOLFOXIRI triplet chemotherapy and is, therefore, evaluable for 5-FU & oxaliplatin and 5-FU & irinotecan. Clinically capecitabine (prodrug 5-FU) is used often, while in in vitro screens 5-FU is evaluated
5-FU 5 Fluorouracil, CAP Capecitabine, ID Identification, PD Progressive disease, PDO Patient-derived organoid, PR Partial response, SD Stable disease